{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daratumumab&page=11",
    "query": {
      "intervention": "daratumumab",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 252,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daratumumab&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daratumumab&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T07:29:11.789Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06042725",
      "title": "MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Chest Radiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Computed Tomography of the Whole Body",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2024-04-11",
      "completion_date": "2027-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06042725"
    },
    {
      "nct_id": "NCT06549634",
      "title": "Biomarkers of AKI in Patients Receiving Daratumumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury",
        "Multiple Myeloma",
        "Light Chain Nephropathy"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-09-01",
      "completion_date": "2026-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06549634"
    },
    {
      "nct_id": "NCT06232707",
      "title": "A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Alnuctamab",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-05-03",
      "completion_date": "2030-09-21",
      "has_results": false,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06232707"
    },
    {
      "nct_id": "NCT04223661",
      "title": "Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide Pill",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Attaya Suvannasankha",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-12-06",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04223661"
    },
    {
      "nct_id": "NCT04205240",
      "title": "Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Srinivas Devarakonda",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2020-12-22",
      "completion_date": "2021-11-22",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04205240"
    },
    {
      "nct_id": "NCT01415882",
      "title": "Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib Citrate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2012-01-31",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01415882"
    },
    {
      "nct_id": "NCT06827860",
      "title": "Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "Talquetamab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Larysa Sanchez",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2025-11-18",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06827860"
    },
    {
      "nct_id": "NCT04176718",
      "title": "Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Multiple Myeloma in Relapse",
        "Relapse"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Yee, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 44,
      "start_date": "2020-05-18",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04176718"
    },
    {
      "nct_id": "NCT02488759",
      "title": "An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Various Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Relatlimab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 578,
      "start_date": "2015-10-13",
      "completion_date": "2022-10-24",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 14,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02488759"
    },
    {
      "nct_id": "NCT02999633",
      "title": "Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-cell Type Acute Leukemia-Precursor",
        "T-lymphoblastic Lymphoma/Leukaemia"
      ],
      "interventions": [
        {
          "name": "Isatuximab SAR650984",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "ranitidine",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-03-08",
      "completion_date": "2017-11-14",
      "has_results": true,
      "last_update_posted_date": "2022-03-21",
      "last_synced_at": "2026-10-29T07:29:11.789Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Hackensack, New Jersey • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02999633"
    }
  ]
}